IDEXX Laboratories, Inc. Q1 2026 Earnings Recap

IDEXX's Q1 results delivered solid organic revenue growth and margin expansion, but the market response was muted with a +2.9% reaction, reflecting investor caution despite raised guidance and favorable fundamentals.

Key Takeaways

• Total revenue grew 14% reported and 11% organically, led by Companion Animal Group (CAG) Diagnostics recurring revenues up 11% organically.
• Despite a 1% decline in U.S. same-store clinical visits, recurring revenues outpaced visits by approximately 1,100 basis points, driven by higher diagnostic utilization and net price improvements (~4%).
• Premium instrument placements surged 28% organically, including 1,100 IDEXX inVue Dx analyzers, with a 12% increase in the premium instrument installed base year-over-year.
• Operating margin expanded by 100 basis points, supported by gross margin gains, resulting in 15% comparable EPS growth to $3.47 per share.
• Full-year 2026 revenue outlook raised to $4.675 billion–$4.76 billion (8.6%–10.6% growth) and EPS guidance increased modestly to $14.45–$14.90, though the market reaction suggests investors remain cautious on the pace of recovery in clinical visits and international headwinds.